StockNews.AI
VERA
StockNews.AI
11 days

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

1. Vera granted stock options and RSUs to new employees on August 4, 2025. 2. 99,000 stock options and 48,200 RSUs were awarded per Nasdaq rules. 3. Stock options have a $20.45 exercise price, aligning with trading on grant date. 4. Vesting occurs over four years, promoting retention of new talent. 5. Vera focuses on treating serious immunological diseases, bolstering future growth.

5m saved
Insight
Article

FAQ

Why Bullish?

The issuance of stock options signals business expansion and attracting talent, which is positive. Given the biotechnology field's volatility, positive talent movements can directly impact stock performance.

How important is it?

Stock options and RSU grants are strategic moves that indicate commitment to innovation, likely enhancing investor confidence.

Why Long Term?

The hiring and retention of new employees through inducement awards suggests growth potential, impacting the company positively over years as new treatments develop.

Related Companies

ATACBKYISTAN
August 08, 2025 16:05 ET  | Source: Vera Therapeutics BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on August 4, 2025 has an exercise price per share equal to $20.45, Vera’s closing trading price on August 4, 2025. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of August 20, 2025, subject to the new employee’s continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant. About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including immunoglobulin A nephropathy (IgAN), also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. Vera also holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. For more information, please visit www.veratx.com. For more information, please contact: Investor Contact:Joyce AllaireLifeSci Advisors 212-915-2569jallaire@lifesciadvisors.com Media Contact:Debra Charlesworth Vera Therapeutics 415-854-8051corporatecommunications@veratx.com

Related News